Pharma BD Deal Intelligence

Cubist Pharmaceuticals Inc. / Optimer Pharmaceuticals Inc.

2013 · Acquisition/Merger · $801M · Complete

Announcement Sentiment

Strongly positive

Cubist to acquire Optimer at $10.75/share + CVR up to $5/share (total up to $801M fully diluted); converted existing Dificid co-promote into outright ownership of CDAD franchise.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Jul 30, 2013
Closed Oct 24, 2013
Deal value $801M
Deal type Acquisition/Merger
Therapeutic area Clostridium difficile-associated diarrhea (CDAD)
Indications Clostridium difficile-associated diarrhea (CDAD)
Key assets Dificid (fidaxomicin)
Mechanism Macrocyclic antibiotic (RNA polymerase inhibitor)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals